Published in Medical Letter on the CDC and FDA, May 10th, 2006
Investigators in the United States report, "Anthrax remains a serious threat worldwide as a bioterrorism agent. A second-generation anthrax vaccine currently under clinical evaluation consists of a recombinant protective antigen (rPA) of Bacillus anthracis. We have previously demonstrated that complete protection against inhalational anthrax can be achieved in a rabbit model, by intranasal delivery of a powder rPA formulation. We describe the preformulation and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.